|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
CTD_human |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
|
12972520 |
2003 |
|
Breast Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
|
12972520 |
2003 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
|
12972520 |
2003 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
|
12972520 |
2003 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
|
12972520 |
2003 |
|
Cardiomyopathies, Primary
|
0.200 |
Biomarker
|
group |
RGD |
An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats.
|
19003918 |
2008 |
|
Myocardial Diseases, Secondary
|
0.200 |
Biomarker
|
group |
RGD |
An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats.
|
19003918 |
2008 |
|
Cardiomyopathies
|
0.200 |
Biomarker
|
group |
RGD |
These results indicate that overexpression of Galpha(i2), PDE2a, and RGS2 down-regulates the beta-adrenergic signaling pathway, thus contributing to the pathogenesis of cirrhotic cardiomyopathy.
|
19003918 |
2008 |
|
Left Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles.
|
12834273 |
2003 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
|
22446963 |
2012 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
|
22446963 |
2012 |
|
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Serum HDL cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Cognition Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
|
28759228 |
2017 |
|
Cognition Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
|
28796496 |
2017 |
|
Cognition Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
|
29093293 |
2017 |
|
Memory Disorders
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results suggest that when evaluating target engagement of PDE2A inhibitors for memory disorder in clinical setting with occupancy assays, the efficacious dose may not fall on the typical receptor/target curve.
|
31253692 |
2019 |
|
Schizophrenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here we characterize the in vivo pharmacological profile of a selective and brain-penetrant PDE2A inhibitor, (<i>N</i>-{(1<i>S</i>)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-<i>b</i>]pyrazine-4(1<i>H</i>)-carboxamide) (TAK-915) as a novel treatment of schizophrenia.
|
29440309 |
2018 |
|
Mechanical Allodynia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Low-Concentration Oxygen/Ozone Treatment Attenuated Radiculitis and Mechanical Allodynia via PDE2A-cAMP/cGMP-NF-<i>κ</i>B/p65 Signaling in Chronic Radiculitis Rats.
|
30651902 |
2018 |
|
Memory Disorders
|
0.020 |
Biomarker
|
disease |
BEFREE |
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.
|
28165743 |
2017 |
|
Schizophrenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results suggest that PDM-631 is a good pharmacological tool that can be used to investigate the role of PDE2A and may have therapeutic potential for the treatment of cognitive impairments associated with schizophrenia and neurodegenerative disorders, without any extrapyramidal side effects.
|
28587776 |
2017 |
|
Mechanical Allodynia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.
|
28283839 |
2017 |
|
Chagas Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mixture-of-isoforms and Enrichr KEGG pathway analyses of the RNA-Seq datasets from ChD (this study) and diabetic (previous study) murine hearts identified alternative splicing (AS) in eleven genes (Arhgef10, Atp2b1, Atp2a3, Cacna1c, Itpr1, Mef2a, Mef2d, Pde2a, Plcb1, Plcb4, and Ppp1r12a) of the cGMP-PKG-Ca<sup>2+</sup> pathway in diseased hearts.
|
31778749 |
2020 |
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results suggest that PDE2A plays a crucial role in the regulation of anxiety by the cGMP/cAMP-dependent pVASP-pCREB-BDNF signaling pathway.
|
30835157 |
2019 |